Hsi Eric D
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA.
Leuk Lymphoma. 2008 Sep;49(9):1668-80. doi: 10.1080/10428190802163339.
Classical Hodgkin lymphoma is now recognised as a B-cell lymphoma. Improved therapy has increased cure rates dramatically; however, relapse and death still occurs in a minority of patients. Much has been learned about the biology of Hodgkin and Reed Sternberg cells and their interactions with the microenvironment, which has informed studies exploring biologic markers that may improve upon clinical prognostic models. This manuscript reviews recent advances in our understanding of the pathobiology of cHL with an emphasis on biologic prognostic markers.
经典型霍奇金淋巴瘤现被公认为是一种B细胞淋巴瘤。改良疗法已显著提高了治愈率；然而，仍有少数患者会复发和死亡。关于霍奇金和里德·斯腾伯格细胞的生物学特性及其与微环境的相互作用，我们已经了解了很多，这为探索可能改进临床预后模型的生物标志物的研究提供了依据。本文综述了我们对cHL病理生物学理解的最新进展，重点是生物预后标志物。
